Shanghai Henlius Biotech, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003N76
HKD
70.75
0.6 (0.86%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Golden Throat Holdings Group Co., Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd.
Shanghai Henlius Biotech, Inc.
Hua Medicine Ltd.
Immunotech Biopharm Ltd.
Transcenta Holding Ltd.
Abbisko Cayman Ltd.
Zhaoke Ophthalmology Ltd.
CStone Pharmaceuticals Co. Ltd.
3D Medicines, Inc.
China Regenerative Medicine International Ltd.

Why is Shanghai Henlius Biotech, Inc. ?

1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.46%
  • Poor long term growth as Operating profit has grown by an annual rate 23.63% of over the last 5 years
  • The company is Net-Debt Free
2
With ROE of 23.84%, it has a Very Expensive valuation with a 6.67 Price to Book Value
  • Over the past year, while the stock has generated a return of 67.65%, its profits have risen by 18.8% ; the PEG ratio of the company is 1.5
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
56.45%
EBIT Growth (5y)
23.63%
EBIT to Interest (avg)
-4.03
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
0.91
Sales to Capital Employed (avg)
0.73
Tax Ratio
3.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.46%
ROE (avg)
10.54%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
6.67
EV to EBIT
30.12
EV to EBITDA
20.16
EV to Capital Employed
4.19
EV to Sales
4.44
PEG Ratio
1.49
Dividend Yield
NA
ROCE (Latest)
13.91%
ROE (Latest)
23.84%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company
OPERATING CASH FLOW(Y)

Highest at HKD 2,510.12 MM

INTEREST COVERAGE RATIO(Q)

Highest at 1,222.94

DEBT-EQUITY RATIO (HY)

Lowest at 71.33 %

RAW MATERIAL COST(Y)

Fallen by 1.34% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 2.58 times

NET SALES(Q)

Highest at HKD 4,211.65 MM

NET PROFIT(Q)

Highest at HKD 481.18 MM

EPS(Q)

Highest at HKD 0.87

-5What is not working for the Company
ROCE(HY)

Lowest at 23.56%

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.57 times

OPERATING PROFIT MARGIN(Q)

Lowest at 15.31 %

Here's what is working for Shanghai Henlius Biotech, Inc.

Interest Coverage Ratio
Highest at 1,222.94 and Grown
In each period in the last five periods
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Cash Flow
Highest at HKD 2,510.12 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Debt-Equity Ratio
Lowest at 71.33 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales
Highest at HKD 4,211.65 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (HKD MM)

Net Sales
At HKD 4,211.65 MM has Grown at 30.35%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (HKD MM)

Net Profit
Highest at HKD 481.18 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (HKD MM)

EPS
Highest at HKD 0.87
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Inventory Turnover Ratio
Highest at 2.58 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by 1.34% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai Henlius Biotech, Inc.

Debtors Turnover Ratio
Lowest at 4.57 times and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Operating Profit Margin
Lowest at 15.31 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Non Operating Income
Highest at HKD 0.21 MM
in the last five periods
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating income